Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation
Myelodysplastic syndromes (MDS) represent a spectrum of senescence-dependent, hematopoietic stem cell disorders 1 with dysplastic cytological features, ineffective hematopoiesis, and a propensity for transformation into acute myeloid leukemia. 2 Response biomarkers to inform delegation of FDA-approved therapies such as the thalidomide analog lenalidomide (Revlimid, Celgene Inc., Warren, NJ, USA) are needed to improve outcomes. High rates of erythroid response to lenalidomide occur in del(5q)-MDS patients because of suppression of haplodeficient phosphatases encoded within the proximal commonly deleted region. 3 A previous report showing that bone marrow lymphoid aggregates appear in association with hematological response implicates immune modulation in this process. 4 Thalidomide, lenalidomide and other structural analogs of this drug class induce potent immune modulation independent of del(5q), with documented activation of T-cells and NK-cells both in vitro and in vivo in multiple myeloma and chronic lymphocytic leukemia. 5 --7 In an effort to understand how lenalidomide's immunomodulatory activity may be linked to hematological response in MDS, we evaluated T-cell activity before and after lenalidomide treatment in vitro, and examined in vivo immune correlation related to hematological response based on International Working Group 2000 criteria. For this analysis, 100 patients with pathologically defined MDS were consented at Moffitt Cancer Center to evaluate immune responses. A total of 13 of these were low-risk, treated with lenalidomide, and had samples collected before and after treatment. Blood samples from an additional five patients with only lenalidomide pretreatment samples available were used for in vitro experiments, but did not contribute to hematological response analysis. Clinical characteristics and lenalidomide responses are shown in Supplementary Table 1 . There was no difference between responders (R) and nonresponders (NR) with regard to international prognostic score, World Health Organization classification or age (P ¼ 0.224).
Figure 1.
Lenalidomide augments T-helper 1 (Th1)-type cytokine production, proliferation, and overcomes inherent anergy in MDS patient T-cells. Proliferation of T-cells was measured by bromodeoxyuridine (BrdU) incorporation after a 2-day culture in the presence of immobilized anti-CD3 antibody (10 mg/ml). The percentage of BrdU-positive cells was determined in both CD4 þ (ai--ii) and CD8 þ T-cells (bi--ii) from 13 MDS patients (MDS) before lenalidomide treatment and 28 healthy donors (Controls) (obtained from the Southwest Florida Blood Services, St Petersburg, FL, USA). T-cells from healthy donors were isolated from buffy coats using RosetteSep Human CD3 þ T-cell Enrichment Cocktail (StemCell Technologies, Vancouver, BC, Canada) according to the manufacturer's protocol. 10 mM BrdU was added during the last 45 min of T-cell stimulation. The cells were fixed and permeabilized with BD Cytofix/Cytoperm buffer (BD Biosciences, San Jose, CA, USA) and incubated with DNase for 1 h at 37 1C. Cells were run on an LSRII flow cytometer (BD Biosciences) and the percentage of BrdU-positive cells from each population were analyzed using Flow-Jo Software (BD Biosciences). A Spearman correlation was used to determine correlation of age and % BrdU incorporation, with insignificant P-values (ai, bi). (c, d) MDS patient PBMCs were treated in vitro with either 5 mM lenalidomide or vehicle control (dimethyl sulfoxide (DMSO)) for 5 days, and stimulated with anti-CD3/CD28 antibodies. The drug was weighed and dissolved at the time of use in DMSO and diluted 1:1000 in culture media to a final concentration of 5 mM because storage of stock solutions at À20 1C resulted in variable loss in activity. On day 5, an aliquot of cells was taken and stained for BrdU incorporation in both CD4 þ and CD8 þ T-cells (ci--ii). The solid line at 17.71 (CD4 þ ) and 17.90 (CD8 þ ) represents the mean proliferation of untreated healthy donor T-cells. Gray shading indicates the normal range of one s.d. above, and one s.d. below the mean (c). Also on day 5, cells were stimulated with phorbol 12-myristate 13-acetate (5 ng/ml) and Ionomycin (250 ng/ml) for 6 h, with the last 4 h in the presence of the protein transport inhibitor Brefeldin-A (10 mg/ml) for intracellular cytokine staining. Cells were collected and incubated in EDTA (2 mM) for 15 minutes at room temperature, fixed with 2% formaldehyde and washed with PBS containing bovine serum albumin. Cells were permeabilized with fluorescence-activated cell sorting permeabilization solution (BD Biosciences) and triple stained with CD3-Pe-Cy5, CD8-fluoroscein isothiocyanate and intracellular cytokines (all PE-conjugated antibodies, BD Biosciences). (d) Flow cytometry was used to determine the percentage of CD4 þ (i) and CD8 þ (ii) interferon-g (IFN-g), tumor necrosis factor-a (TNF-a), IL À2, À4, and À10 secreting cells. The difference between Len-and DMSO-treated samples for each patient is shown. (a--d) A Wilcoxon-rank sum test was used to compare the mean proliferation between healthy donor and MDS patient samples (a, bii), and between stimulated and unstimulated samples (ci--ii). A Wilcoxon-rank sum test was used to determine statistical difference between Len-and DMSO-treated groups, with DMSO treatment used as baseline cytokine secretion (di--ii); P-values are indicated. Figure 2 . Lenalidomide reverses T-cell tolerance in MDS patients with hematological response through increased proliferation and cytokine production, and increased naïve T-cell reconstitution in vivo. Characteristics of the 13 MDS patients treated with lenalidomide in vivo are described in Supplementary Table 1 . Seven patients exhibited a major erythroid response out of 13 (53.8%), as determined by International Working Group 2000 criteria. The median age of the group was 74 (range 49--83) and the median age of the R was 72 years (mean 68.3, range 53--79 years), which did not differ from the nonresponders (NR) (median 78.5, mean 73.5, range 49--83) (P ¼ 0.224). Two patients with del(5q) were treated, one with del(2)(q11.2), one with complex abnormalities and the remaining patients had a normal karyotype (n ¼ 9). All patients, including the patients with del(5q), were treated for severe anemia and the responsive patients demonstrated a sustained increase in hemoglobin for at least 4 weeks duration. Patients with del(5q) also had a complete cytogenetic response with elimination of the clonal myeloid cells. The mean hemoglobin for the group was 9.1 g/dl, absolute neutrophil count 3.22 Â 10 9 cells/l and platelet count was required to be 450 000 cells/l for eligibility on the clinical trial. (a) Schematic of patient sample collection and lenalidomide treatment during clinical trial. (b--e) PBMCs were collected from MDS patients (n ¼ 13) before (pre) and 16 weeks after (post) receiving lenalidomide therapy. Patients were evaluated using the International Working Group 2000 criteria for response, with seven responders (R) and six NR. (b) Cells were stained for CD3, CD8, CD45RA, CD62L and 4,6-diamidino-2-phenylindole (DAPI) as described in Supplementary Figure 1 . The proportion of naïve, central memory, effector memory, and terminal effector memory T-cells for both CD4 and CD8 was determined using flow cytometry. Naïve cells are described as CD3 þ CD62 L þ CD45RA þ , central memory (CM) as CD3 þ CD62L þ CD45RA À , effector memory (EM) as CD3 þ CD62 L À CD45RA À and terminal effector memory (TEM) are described as CD3 þ CD62 L À CD45RA þ . The difference post-pre of each of the phenotypes within responding and nonresponding patients is shown. Statistical analysis was performed using Wilcoxon-rank sum. P-values are indicated. (c) Cells were cultured in the presence of anti-CD3/CD28 antibodies for 48 h before measurement of BrdU incorporation. Percentage of proliferating CD4 þ (upper) and CD8 þ (lower) T-cells was determined by flow cytometry. The difference in proliferation (post-pre) was analyzed using Wilcoxon-rank sum test, with P-values indicated. (d--e) In vivo cytokine production was determined for both CD4 (d) and CD8 (e) T-cells. PBMCs were stimulated for 48 h with CD3/CD28 antibodies, and then for the last 6 h with phorbol 12-myristate 13-acetate/ionomycin. Golgi-block and cytokine staining was performed as described in Figure 1d . (f) MDS patient PBMCs were stimulated with antiCD3/antiCD28 antibodies and the percentage difference (post-treatmentÀpre-treatment) of naïve CD4 þ (i) and CD8 þ (ii) T-cells after treatment with lenalidomide in both R and NR was correlated with age. A trend line was created for both R and NR in both the CD4 þ and CD8 þ populations. Data was analyzed via Spearman's correlation test. P-values are indicated, as well as correlation of the data to the trend line (Spearman's r), with 1 or À1 representing a perfect correlation. NR are represented by an open triangle symbol; R are represented by closed circle.
To evaluate basal T-cell competency in pre-lenalidomidetreated patient samples (n ¼ 13) compared with healthy donors (n ¼ 28), the T-cell receptor complex was stimulated by anti-CD3 antibody-cross-linking, and proliferation was determined. Figures  1a and b show that the percentage of stimulated T-cells induced to proliferate was significantly less in patient samples compared with controls for both CD4 þ and CD8 þ -T-lymphocyte subsets (Po0.0001). This functional difference was age-independent, as shown in Figures 1ai and bi, indicating that MDS T-cells are anergic, or hypo-responsive, to T-cell stimulation.
Defective proliferation in incompletely tolerant T-cells can be rescued by high doses of exogenous interleukin-2 (IL-2). 8 We therefore examined anti-CD3-induced proliferation in the presence and absence of IL-2 (data not shown). Although a 57% increase in CD4 and CD8 T-cell proliferation was observed, the amount of TCR-stimulated proliferation in the presence of IL-2 in cases was still significantly lower than that of healthy donors. Peripheral blood mononuclear cells (PBMCs) were cultured with lenalidomide in vitro during anti-CD3/CD28 antibody stimulation to assess effects of the drug on these tolerant, or hyporesponsive, T-cells in MDS patients. PBMCs from 18 (untreated) MDS patients were stimulated in the presence of 5 mM lenalidomide or vehicle (dimethyl sulfoxide), and proliferation was determined by bromodeoxyuridine incorporation. Data in Figure 1ci --ii shows significantly greater TCR-induced proliferation in CD4 þ (Po0.001) and CD8 þ (Po0.001)-treated T-cells after lenalidomide compared with dimethyl sulfoxide, and in some cases, proliferation was restored to the level of healthy donors as indicated (shaded region) ( Figure 1c ). Lack of proliferation to lenalidomide without TCR stimulation (Unstim) indicates the drug has no direct mitogenic activity in T-cells ( Figure 1c ).
In addition to proliferation, lenalidomide-treated T-cells increased TCR-stimulated cytokine production (Figure 1di --ii) . The cytokine response favored T-helper 1-type cytokines including interferon-g, tumor necrosis factor-a and IL-2, which are effectors of antitumor immunity and potentially important for the elimination of premalignant or dysplastic myeloid clones. As shown in Figure 1di --ii, lenalidomide either decreased (IL-4) or induced no change (IL-10) in T-helper 2 (Th2) cytokines. As lenalidomide increased the liberation of effector cytokines and augmented proliferation of both CD4 þ and CD8 þ T-cell subsets, its effect on hematopoiesis may be mediated by eradication of specific abnormal myeloblasts involved in MDS clonal evolution. In support of this idea, Neuber et al. 5 recently reported an enhanced antigen-specific T-cell activity in vitro and in vivo in multiple myeloma patients, indicating that lenalidomide can potentiate tumoricidal activity of effector T-cells.
Although lenalidomide is able to increase function in anergic MDS T-cells in vitro, the in vivo immunological response in MDS patients treated for anemia has not been examined. First, the change (%postÀpre) was calculated for CD4 þ and CD8 þ T-cells with a naïve, central memory (CM), effector memory and terminal effector memory phenotype using multicolor flow cytometry analysis, as detailed in Supplementary Figure 1 in R (n ¼ 7) and NR (n ¼ 6). Samples for this analysis were collected before (pre) and 16 weeks after lenalidomide therapy (post), as shown in Figure 2a . Memory phenotype skewing has been previously reported in MDS and correlated to chronic immune activation in vivo. 9 Cells with the terminal effector memory phenotype represent a unique, poorly studied, population of effector cells that are generally senescent, lack the CD28 co-stimulatory molecule, and increase through aging and autoimmunity. 10, 11 Figure 2b shows that the percentage of naïve CD4 and CD8 T-cells are significantly increased (P ¼ 0.004 and P ¼ 0.003, respectively), whereas CD4 and CD8 effector memory (P ¼ 0.046 and P ¼ 0.02, respectively) and terminal effector memory (P ¼ 0.0032 and P ¼ 0.015, respectively) decreased significantly after lenalidomide therapy. Lenalidomide increased CD8 þ CM T-cells (P ¼ 0.004, Figure 2b ) with a similar trend in CD4 þ CM cells (P ¼ 0.09). Thus, changes in the composition of the peripheral T-cell compartment were significantly associated with an erythroid response in MDS. Lack of an increase in total lymphocytes ( Supplementary Figure 2) suggests that the observed improvement in naïve and CM T-cells may be because of improved homeostatic balance within the T-cell compartment. 12 Next, we calculated the percentage change in bromodeoxyuridine-positive cells (%postÀpre) in R and NR after ex vivo anti-CD3 antibody-stimulation in lenalidomide-treated patient samples collected and analyzed as shown in Figure 2 . The percent increase in proliferation was significantly greater in R compared with NR after therapy (Figure 2c , P ¼ 0.03 CD4; P ¼ 0.004 CD8) without an absolute increase in lymphocytes ( Supplementary Figure 2) . The ability of T-cells to produce cytokines was also determined by intracellular flow cytometry in R and NR in ex vivo TCR-stimulated cells (Figures 2d and e ). IL-2 (P ¼ 0.05 CD4; P ¼ 0.01 CD8), interferon-g (P ¼ 0.03 CD4; P ¼ 0.01 CD8) and tumor necrosis factor-a (P ¼ 0.004 CD4; P ¼ 0.01 CD8) secreting CD4 (d) and CD8 (e) T-cells were increased significantly more after lenalidomide in R compared with NR. R, however, had either no change or a decrease in Th2-type cytokines (IL-4 and IL-10)) ( Figures 2d and e) , indicating that the type of T-cell immune response is similar to lenalidomide treatment in vitro.
On the basis of these data, we conclude that lenalidomide improves functional response in anergic T-cells in MDS, not by acting as a mitogen, but by augmenting T-cell receptor-induced signals. A significant improvement in the ratio of naïve-to-memory T-cells, increased cytokine production and increased proliferation was evident in MDS patients with erythropoietic activity to lenalidomide (Figure 2b) . Preferential augmentation of naïve T-cells suggests that lenalidomide increases proliferation, thymic output or a combination of both in addition to improving homeostasis within the T-cell compartment. 13, 14 We then determined the association between proliferation, cytokine production and naïve T-cell changes. The percentage change in naïve T-cells showed a significant positive correlation with the change in proliferative response (CD4, P ¼ 0.0003 and CD8, P ¼ 0.0220) ( Supplementary Figure 3) and interferon-g production (CD8 T-cells, P ¼ 0.0118 and CD4 þ T-cells, P ¼ 0.0941), although the latter in CD4 þ T-cells was not statistically significant ( Supplementary Figure 3) . Positive correlations were also identified between IL-2 production and changes in naïve T-cells in both subsets (CD4, P ¼ 0.0118 and CD8, P ¼ 0.0428, respectively), suggesting that reconstitution of the naïve T-cell compartment is at least partially responsible for improved function that is associated with hematological response.
Our findings, therefore, implicate homeostatic reconstitution of naive T-cells in hematological improvement in low-risk MDS patients. It was shown that treatment with lenalidomide restored differentiation potential accompanied by upregulation of the natively suppressed erythroid gene signature in a select subgroup of anemic patients with non-del5q MDS. 15 It is possible that lenalidomide stimulates not only erythropoiesis, but also restores naïve T-cells by increasing lymphopoiesis. If so, the production of naïve T-cells may be limited by age-dependent thymic involution. In support of this idea, the change in naïve CD4 þ T-cells after lenalidomide was significantly less with age (r ¼ À0.92, P ¼ 0.007; Figure 2fi ), suggesting that an age-related process, such as thymic involution, may limit the increase in naïve T-cells. Changes in naïve CD8 þ T-cells, by contrast, was age-independent ( Figure 2fii ) in both NR and R (P ¼ 0.224) indicating that these two T-cell subsets are mechanistically different. To confirm thymic involvement, examination of T-cell receptor excision circles to identify recent thymic emigrants is needed. However, the relationship between lenalidomide and therapeutic response preference in younger MDS patients has been documented in a large cohort, suggesting that age-dependent immune modulation may have a role. 16 In summary, establishment of normal T-cell homeostasis, increased effector function and reduction in T-cell tolerance is associated with hematological improvement after lenalidomide treatment in MDS. Our data provides a rationale to examine a larger cohort of patients to determine whether basal T-cell function is predictive for response to lenalidomide in MDS. Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal B lymphocytes in blood, bone marrow (BM) and secondary lymphoid tissues. The prognosis of the disease is heterogeneous, with no or a low number of somatic hypermutations in the variable region of immunoglobulin genes (IGHV), high expression of ZAP-70 or CD38, and the presence of certain cytogenetic abnormalities, being all associated with poor prognosis. 1 Despite the development of more effective treatments, CLL remains incurable with standard therapy.
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Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells
The multikinase inhibitor sorafenib, which has been approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has emerged in the last years as a promising agent for treating tumors in which oncogenic kinases are frequently deregulated. 2 Recent studies have shown that CLL cells might be also susceptible to this compound. 3, 4 Thus, sorafenib could be particularly relevant in CLL cells by blocking RAF-mediated survival responses in the presence of CXCL12, 4 its cytotoxic effect being related to the translational inhibition of the antiapoptotic protein MCL-1. 3 In this context, the aim of our study was to investigate the capacity of sorafenib to interfere with B-cell receptor (BCR) signaling and to evaluate its efficacy in modulating migratory and microenvironmental prosurvival signals.
Peripheral blood (PB), BM or lymph node (LN) samples from CLL patients (n ¼ 45) were incubated with sorafenib at doses ranging from 2.5 to 15 mM. The biological characteristics of CLL patients are listed in Supplementary Table 1 . In agreement with previous reports, 3, 4 we confirmed that sorafenib induced a dose-dependent apoptosis in all CLL samples, including those bearing adverse cytogenetic alterations, with a mean lethal dose 50 of 9.71 ± 2.14 mM at 24 h (Supplementary Table 1 and Supplementary Figure 1A ). The unmutated IGHV group was significantly more sensitive than the mutated IGHV group (*P ¼ 0.01; Supplementary Figure 1B) . Importantly, as shown in Figure 1a , the sensitivity to sorafenib of PB mononuclear cells from healthy donors was significantly lower when compared with CLL cells (***Po0.001), both in T lymphocytes (CD3 þ cells) and B lymphocytes (CD19 þ cells). Thus, these results demonstrate that the cytotoxic effect of sorafenib is selective for tumoral lymphocytes, at least in the range of doses achievable in vivo. 5 Noteworthy, we compared the sensitivity to sorafenib of CLL cells obtained simultaneously from the three compartments, PB, LN and BM, and as shown in Figure 1b , sorafenib was significantly more cytotoxic in CD19 þ lymphocytes isolated from LN than those from PB or BM (***Po0.001 at 7.5 mM; **Po0.01 at 10 mM).
As previously reported, 3 we confirmed that sorafenib induced a downregulation of MCL-1 in CLL cells, due to the translational inhibition of this antiapoptotic protein ( Supplementary Figure 2A) . However, the basal levels of MCL-1 did not correlate with
